Actelion Ltd. | Cash Flow

Fiscal year is January-December. All values CHF Thousands.
2012
2013
2014
2015
2016
Net Income before Extraordinaries
303,226.00
452,542.00
593,796.00
547,935.00
694,835.00
Depreciation, Depletion & Amortization
81,888.00
84,460.00
101,081.00
89,500.00
87,879.00
Other Funds
2,769.00
3,353.00
12,417.00
14,551.00
15,097.00
Funds from Operations
441,539.00
527,939.00
704,023.00
709,487.00
890,507.00
Changes in Working Capital
130,812.00
64,042.00
545,446.00
51,809.00
29,023.00
Net Operating Cash Flow
572,351.00
591,981.00
158,577.00
657,678.00
919,530.00
Capital Expenditures
39,278.00
27,421.00
29,237.00
43,980.00
57,442.00
Purchase/Sale of Investments
4,179.00
-
-
-
-
Net Investing Cash Flow
117,824.00
408,200.00
218,821.00
51,995.00
61,681.00
Cash Dividends Paid - Total
93,686.00
113,297.00
133,389.00
142,390.00
158,513.00
Issuance/Reduction of Debt, Net
61.00
61.00
61.00
1,030.00
148,206.00
Net Financing Cash Flow
332,663.00
315,045.00
418,468.00
1,159,791.00
618,914.00
Net Change in Cash
111,823.00
144,632.00
31,380.00
564,033.00
238,694.00
Free Cash Flow
538,643.00
570,585.00
133,538.00
638,975.00
886,726.00
Deferred Taxes & Investment Tax Credit
-
89,592.00
86,570.00
52,068.00
30,353.00
Net Assets from Acquisitions
27,442.00
230,779.00
895.00
8,015.00
4,239.00
Other Sources
450,000.00
100,000.00
450,747.00
-
-
Change in Capital Stock
241,685.00
205,040.00
297,435.00
1,032,982.00
623,704.00
Exchange Rate Effect
10,041.00
13,368.00
9,690.00
9,925.00
241.00
Other Uses
505,283.00
250,000.00
201,794.00
-
-

About Actelion

View Profile
Address
Gewerbestrasse 16
Allschwil Basel-Landschaft (Basle Country) 4123
Switzerland
Employees -
Website http://www.actelion.com
Updated 07/08/2019
Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs. It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs. Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.